These CAR-T cells can be derived from a patient’s own T cells (autologous) or from donor cells (allogeneic) and have demonstrated significant success in targeting key antigens like CD19 and B-cell maturation antigen (3), which are prevalent in B-cell malignancies and plasma cell tumors (4–6). Here, CD19 is linked to plasma cell neoplasm.